No Data
No Data
We're A Little Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Cognition Therapeutics (CGTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Express News | HC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $5 Price Target
Cognition Therapeutics Analyst Ratings
Positive Clinical Trial Developments and Financial Position Drive Buy Rating for Cognition Therapeutics
Cognition Therapeutics Provided an Update on Phase 2 'SHINE' Study Analysis